Steven Cohen Aadi Bioscience, Inc. Transaction History

Point72 Asset Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$6.85 - $13.0 $451,963 - $857,740	-65,980 Reduced 99.87%	86 $0
Q4 2022 Feb 14, 2023	SELL	$11.99 - $14.5 $6.01 Million - $7.27 Million	-501,063 Reduced 88.35%	66,066 $847,000
Q3 2022 Nov 14, 2022	BUY	$12.03 - $14.22 $301,772 - $356,708	25,085 Added 4.63%	567,129 $8.01 Million
Q2 2022 Aug 15, 2022	BUY	$11.57 - $17.92 $3.82 Million - $5.92 Million	330,513 Added 156.25%	542,044 $6.68 Million
Q1 2022 May 16, 2022	BUY	$16.65 - $24.97 $3.52 Million - $5.28 Million	211,531 New	211,531 $3.59 Million

12.6M

23.8K

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $63.1M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.